FORMULATION OF DIRECTLY COMPRESSED PHENYTOIN SODIUM ORALLY DISINTEGRATING TABLETS BY SIMPLEX LATTICE DESIGN USING AVICEL® PH 102 AND ERA-TAB® AS DILUENTS
Main Article Content
Abstract
The orally disintegrating tablets (ODT) consisted of phenytoin sodium (PS), a poorly water-soluble drug, were prepared by direct compression. According to simplex lattice design; the various ratios of the two direct compressible diluents, microcrystalline cellulose (Avicel® PH102) and spray-dried rice starch (Era-Tab®) utilized in the tablet formulations were predetermined. Cross-linked polyvinylpyrrolidone (crospovidone, Polyplasdone® XL) was used as disintegrant. Saccharin sodium, magnesium stearate and talcum were used as sweetening agent, lubricant and glidant, respectively. The prepared tablet formulations provided disintegration times between 4 to 107 seconds. The tablet formulation containing 1:0 Avicel® PH 102:Era-Tab® provided the fastest disintegration times of 4 seconds. From the obtained tablet disintegration times, the equation representing the relationship between disintegration time and the ratio of Avicel® PH 102 to Era-Tab® was constructed. From this equation, the validated formulations containing 0.17:0.33, 0.33:0.67 and 0.67:0.33 Avicel® PH102:Era-Tab® were prepared and tested for tablet disintegration. The tablet formulation yielded the observed and predicted disintegration times of 81, 51, 12 and 75, 51, 16 seconds, respectively. The tablet formulations containing 1:0 and 0.67:0.33 Avicel® PH 102:Era-Tab® which exhibited the fastest disintegration times were tested for tablet dissolution. Their percentages of drug dissolution at the 30th minute time interval were 69% and 87%, respectively. The tablet formulation containing 0.67:0.33 Avicel® PH 102:Era-Tab® met the USFDA disintegration time requirement for ODT and passed the USP criteria for prompt phenytoin sodium dissolution test.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Journal of TCI is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence, unless otherwise stated. Please read our Policies page for more information.
References
Name AB, Na Battu SK, Repka MA, Majumdar S, Rao MY. 2007. Formulation and evaluation of rapidly disintegrating fenoverine tablets: Effect of superdisintegrants. Drug Dev. Ind. Pharm. 33:1225–32.
Bolton S. 1986. Statistical applications in the pharmaceutical sciences. In: Lachman L, Liberman HA, Kanig JL editors. The theory and practice of industrial pharmacy. 3rd ed. Philadelphia: Lea&Febiger; pp. 283-5.
Botzolakis JE, Augsburger LL. 1988. Disintegrating agents in hard gelatin capsules. Part I: Mechanism of action, Drug Dev. Ind. Pharm. 14(1):29-41.
Dangprasirt P. 2015. Formulation of propranolol hydrochloride orally disintegrating tablets by direct compression using simplex lattice design. Bull. Health Sci. Technol. 13(2): 39-46.
Hirani JJ, Rathod DA, Vadalla KR. 2009. Orally Disintegrating Tablets: A Review. Trop. J. Pharm. Res. 8(2): 161-72.
Kumar GP, Nirmala. R. 2012. Fundamental aspects of superdisintegrants: a concise review. J. Global Pharm. Technol. 4(2): 1-12.
Moreton RC. 2008. Disintegrants in tableting. In: Ausburger LL, Hoag SW, editors. Pharmaceutical dosage forms: tablets. Volume 2. 3rd ed. New York: Informa Healthcare; pp 240.
Rowe RC, Sheskey, PJ, Quinn., ME. 2009. Handbook of pharmaceutical excipients. 6th ed. Chicago: Pharmaceutical Press.
Scheffe H. 1963. Simplex-centroid design for experiments with mixtures. J. R. Stat. Soc. B. 25: 235-63.
The Department of Health, Great Britain. The Department of Health, Social, Services and Public Safety, Northern Ireland. 2015. British Pharmacopoeia. Volume V. London: The Stationary Office. Appendix XII C V-371.
The United States Pharmacopeia. The National Formulary. 2014. USP 37 and NF 32. Volume 1.1. Volume 1.3 Volume 3.2. Rockville: The United States Pharmacopeial Convention.
U.S. Department of Health and Human Services. Food and Drug Administration. 2008. Guidance for Industry: Orally Disintegrating Tablets. Rockville: Center for Drug Evaluation and Research.